Responses to Parliamentary Inquiries: Brexit and Genome Editing
Last Reviewed 30/10/2017
In recent weeks we have contributed responses to three parliamentary inquiries:
House of Lords Select Committee on Science and Technology Call for Evidence on Life Sciences and the Industrial Strategy.
The Committee’s inquiry considered the recently published life sciences industrial strategy, which the Government asked Sir John Bell to work on as part of its wider industrial strategy. The committee was seeking views on the content of the strategy and the role of the Government and business in its development and implementation.
Science and Technology Committee (Commons) Genomics and genome editing in the NHS inquiry.
The Committee invited evidence on the Chief Medical Officer’s latest annual report, ‘Generation Genome’, and its recommendations on mainstreaming genomic medicine in the NHS within 5 years. This includes observations on how any barriers to greater integration of genomic therapies in the NHS could be overcome, and how such barriers may differ across the devolved nations.
Health Select Committee Brexit – medicines, medical devices and substances of human origin inquiry.
The inquiry asked about what new regulatory arrangements must be put in place from 29 March 2019 to guarantee the safe and effective supply of medicines, medical devices, medical products and substances of human origin in the UK. This includes what the implications are for medical research and development, including for the timely patient access to new medicines, and other relevant medical innovations developed within or outside the UK.
If you have any questions about this work, please contact our Policy Officer, Louise.